WO2001051083A3 - Innate immunity-stimulating compositions of cpg and saponin and methods thereof - Google Patents

Innate immunity-stimulating compositions of cpg and saponin and methods thereof Download PDF

Info

Publication number
WO2001051083A3
WO2001051083A3 PCT/US2001/001046 US0101046W WO0151083A3 WO 2001051083 A3 WO2001051083 A3 WO 2001051083A3 US 0101046 W US0101046 W US 0101046W WO 0151083 A3 WO0151083 A3 WO 0151083A3
Authority
WO
WIPO (PCT)
Prior art keywords
saponin
innate immunity
cpg
methods
stimulating compositions
Prior art date
Application number
PCT/US2001/001046
Other languages
French (fr)
Other versions
WO2001051083A2 (en
Inventor
Charlotte R Kensil
Original Assignee
Aquila Biopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aquila Biopharm Inc filed Critical Aquila Biopharm Inc
Priority to EP01902032A priority Critical patent/EP1250150A2/en
Priority to CA002397374A priority patent/CA2397374A1/en
Priority to AU27877/01A priority patent/AU781812B2/en
Priority to JP2001551506A priority patent/JP2003527352A/en
Publication of WO2001051083A2 publication Critical patent/WO2001051083A2/en
Publication of WO2001051083A3 publication Critical patent/WO2001051083A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Compositions comprising oligonucleotides comprising at least one unmethylated CpG dinucleotide and saponin and the use thereof for stimulating innate immunity and enhancing natural killer cell activity are disclosed.
PCT/US2001/001046 2000-01-13 2001-01-12 Innate immunity-stimulating compositions of cpg and saponin and methods thereof WO2001051083A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01902032A EP1250150A2 (en) 2000-01-13 2001-01-12 Innate immunity-stimulating compositions of cpg and saponin and methods thereof
CA002397374A CA2397374A1 (en) 2000-01-13 2001-01-12 Innate immunity-stimulating compositions of cpg and saponin and methods thereof
AU27877/01A AU781812B2 (en) 2000-01-13 2001-01-12 Innate immunity-stimulating compositions of CPG and saponin and methods thereof
JP2001551506A JP2003527352A (en) 2000-01-13 2001-01-12 Innate immune stimulating compounds of CPG and saponin and methods thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17584000P 2000-01-13 2000-01-13
US60/175,840 2000-01-13
US20085300P 2000-05-01 2000-05-01
US60/200,853 2000-05-01
US36994100A 2000-08-06 2000-08-06
US09/369,941 2000-08-06

Publications (2)

Publication Number Publication Date
WO2001051083A2 WO2001051083A2 (en) 2001-07-19
WO2001051083A3 true WO2001051083A3 (en) 2002-01-03

Family

ID=27390599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001046 WO2001051083A2 (en) 2000-01-13 2001-01-12 Innate immunity-stimulating compositions of cpg and saponin and methods thereof

Country Status (4)

Country Link
JP (1) JP2003527352A (en)
AU (1) AU781812B2 (en)
CA (1) CA2397374A1 (en)
WO (1) WO2001051083A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ES2572834T3 (en) 1999-02-17 2016-06-02 Csl Limited Immunogenic complexes and related methods
DK1187629T3 (en) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
US20020098199A1 (en) * 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
EA005823B1 (en) 2000-03-31 2005-06-30 Пердью Рисерч Фаундейшн Method of treatment using immunogen conjugates
EP1326638B9 (en) * 2000-10-18 2008-02-20 GlaxoSmithKline Biologicals S.A. Vaccines against cancers
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
KR20040053136A (en) * 2001-09-28 2004-06-23 펄듀 리서치 파운데이션 Method of treatment using ligand-immunogen conjugate
JP5153990B2 (en) 2001-12-21 2013-02-27 シーエスエル、リミテッド Compositions containing immunoreactive reagents and saponins, and methods of use thereof
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
JP4598519B2 (en) * 2002-06-20 2010-12-15 サイトス バイオテクノロジー アーゲー Packaged virus-like particles for use as adjuvants: preparation and use
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
JP4976848B2 (en) 2003-02-20 2012-07-18 ユニバーシティー オブ コネティカット ヘルス センター Methods and compositions for the treatment of cancer and infectious diseases using alpha (2) macroglobulin-antigen molecule complexes
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
RU2015117604A (en) 2009-04-03 2015-10-27 Эйдженус Инк. METHODS FOR PRODUCING AND USING MULTI-CHAPERON-ANTIGENIC COMPLEXES
JP6045895B2 (en) 2012-10-01 2016-12-14 株式会社トプコン Ophthalmic observation device
JP6925980B2 (en) 2015-05-13 2021-08-25 アジェナス インコーポレイテッド Vaccines for the treatment and prevention of cancer
CA2972175C (en) 2016-07-29 2022-03-01 Trinidad Schlotterbeck Suarez Use of quillaja saponaria extracts for the prevention and control of bacterial infections in fish
WO2018018171A1 (en) 2016-07-29 2018-02-01 Saponin Research Center S.A. Use of extracts of quillaja saponaria for the prevention and control of viral infections in fish
US20200289889A1 (en) 2019-03-11 2020-09-17 Rom Technologies, Inc. Bendable sensor device for monitoring joint extension and flexion
US11185735B2 (en) 2019-03-11 2021-11-30 Rom Technologies, Inc. System, method and apparatus for adjustable pedal crank
US11471729B2 (en) 2019-03-11 2022-10-18 Rom Technologies, Inc. System, method and apparatus for a rehabilitation machine with a simulated flywheel
US11957960B2 (en) 2019-05-10 2024-04-16 Rehab2Fit Technologies Inc. Method and system for using artificial intelligence to adjust pedal resistance
US11801423B2 (en) 2019-05-10 2023-10-31 Rehab2Fit Technologies, Inc. Method and system for using artificial intelligence to interact with a user of an exercise device during an exercise session
US11904207B2 (en) 2019-05-10 2024-02-20 Rehab2Fit Technologies, Inc. Method and system for using artificial intelligence to present a user interface representing a user's progress in various domains
US11071597B2 (en) 2019-10-03 2021-07-27 Rom Technologies, Inc. Telemedicine for orthopedic treatment
US11701548B2 (en) 2019-10-07 2023-07-18 Rom Technologies, Inc. Computer-implemented questionnaire for orthopedic treatment
US11075000B2 (en) 2019-10-03 2021-07-27 Rom Technologies, Inc. Method and system for using virtual avatars associated with medical professionals during exercise sessions
US11955221B2 (en) 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for using AI/ML to generate treatment plans to stimulate preferred angiogenesis
US11915815B2 (en) 2019-10-03 2024-02-27 Rom Technologies, Inc. System and method for using artificial intelligence and machine learning and generic risk factors to improve cardiovascular health such that the need for additional cardiac interventions is mitigated
US11756666B2 (en) 2019-10-03 2023-09-12 Rom Technologies, Inc. Systems and methods to enable communication detection between devices and performance of a preventative action
US12062425B2 (en) 2019-10-03 2024-08-13 Rom Technologies, Inc. System and method for implementing a cardiac rehabilitation protocol by using artificial intelligence and standardized measurements
US11515021B2 (en) 2019-10-03 2022-11-29 Rom Technologies, Inc. Method and system to analytically optimize telehealth practice-based billing processes and revenue while enabling regulatory compliance
US11955223B2 (en) 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for using artificial intelligence and machine learning to provide an enhanced user interface presenting data pertaining to cardiac health, bariatric health, pulmonary health, and/or cardio-oncologic health for the purpose of performing preventative actions
US11101028B2 (en) 2019-10-03 2021-08-24 Rom Technologies, Inc. Method and system using artificial intelligence to monitor user characteristics during a telemedicine session
US11069436B2 (en) 2019-10-03 2021-07-20 Rom Technologies, Inc. System and method for use of telemedicine-enabled rehabilitative hardware and for encouraging rehabilitative compliance through patient-based virtual shared sessions with patient-enabled mutual encouragement across simulated social networks
US12020800B2 (en) 2019-10-03 2024-06-25 Rom Technologies, Inc. System and method for using AI/ML and telemedicine to integrate rehabilitation for a plurality of comorbid conditions
US12020799B2 (en) 2019-10-03 2024-06-25 Rom Technologies, Inc. Rowing machines, systems including rowing machines, and methods for using rowing machines to perform treatment plans for rehabilitation
US11955222B2 (en) 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for determining, based on advanced metrics of actual performance of an electromechanical machine, medical procedure eligibility in order to ascertain survivability rates and measures of quality-of-life criteria
US11887717B2 (en) 2019-10-03 2024-01-30 Rom Technologies, Inc. System and method for using AI, machine learning and telemedicine to perform pulmonary rehabilitation via an electromechanical machine
US11961603B2 (en) 2019-10-03 2024-04-16 Rom Technologies, Inc. System and method for using AI ML and telemedicine to perform bariatric rehabilitation via an electromechanical machine
US11915816B2 (en) 2019-10-03 2024-02-27 Rom Technologies, Inc. Systems and methods of using artificial intelligence and machine learning in a telemedical environment to predict user disease states
US11978559B2 (en) 2019-10-03 2024-05-07 Rom Technologies, Inc. Systems and methods for remotely-enabled identification of a user infection
US11923065B2 (en) 2019-10-03 2024-03-05 Rom Technologies, Inc. Systems and methods for using artificial intelligence and machine learning to detect abnormal heart rhythms of a user performing a treatment plan with an electromechanical machine
US11830601B2 (en) 2019-10-03 2023-11-28 Rom Technologies, Inc. System and method for facilitating cardiac rehabilitation among eligible users
US11955220B2 (en) 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for using AI/ML and telemedicine for invasive surgical treatment to determine a cardiac treatment plan that uses an electromechanical machine
US11826613B2 (en) 2019-10-21 2023-11-28 Rom Technologies, Inc. Persuasive motivation for orthopedic treatment
TW202128217A (en) 2019-12-13 2021-08-01 大陸商遠大賽威信生命科學（南京）有限公司 Pharmaceutical composition and use thereof
US11107591B1 (en) 2020-04-23 2021-08-31 Rom Technologies, Inc. Method and system for describing and recommending optimal treatment plans in adaptive telemedical or other contexts
CN113223690B (en) * 2020-07-06 2022-10-11 罗姆科技股份有限公司 Method and system for rehabilitating a subject via telemedicine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1999061056A2 (en) * 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity
WO2000009159A1 (en) * 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
WO2000062800A2 (en) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1999061056A2 (en) * 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity
WO2000009159A1 (en) * 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
WO2000062800A2 (en) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM SOO KIE ET AL: "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.", VACCINE, vol. 19, no. 4-5, 15 October 2000 (2000-10-15), pages 530 - 537, XP000999847, ISSN: 0264-410X *

Also Published As

Publication number Publication date
CA2397374A1 (en) 2001-07-19
AU781812B2 (en) 2005-06-16
JP2003527352A (en) 2003-09-16
WO2001051083A2 (en) 2001-07-19
AU2787701A (en) 2001-07-24

Similar Documents

Publication Publication Date Title
WO2001051083A3 (en) Innate immunity-stimulating compositions of cpg and saponin and methods thereof
AU2001227889A1 (en) Oligodeoxynucleotide and its use to induce an immune response
MXPA03002453A (en) Use of immidazoquinolinamines as adjuvants in dna vaccination.
AU2002239273A1 (en) Fabric softening compositions and methods
AU2001269742A1 (en) Method of treating gastrointestinal diseases associated with species of genus clostridium
EP1404182A4 (en) Pre-proofed freezer-to-oven dough compositions, and methods
AU2001285143A1 (en) Methods and compositions for targeted delivery
AU2002353783A1 (en) SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
AU2001260847A1 (en) Compositions isolated from skin cells and methods for their use
WO2004005476A3 (en) Nucleic acid compositions for stimulating immune responses
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
AU2001241918A1 (en) Methods of enhancing activity of vaccines and vaccine compositions
MXPA03000488A (en) Gel form automatic dishwashing compositions, methods of preparation and use thereof.
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2002230888A1 (en) Methods and compositions to treat conditions associated with neovascularization
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
AU2001275155A1 (en) Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same
AU5647601A (en) Hair treatment compositions
AU2001222215A1 (en) Lumbago treating girdle
IL144845A0 (en) Vaccines and gene therapy compositions and methods of making and using the same
AU2001245489A1 (en) Human single nucleotide polymorphisms
AU2001240018A1 (en) Adeno-associated viral compositions and methods
AU2003217309A1 (en) Novel pyranosyl cytosines: pharmaceutical formulations and methods
AU2003210704A1 (en) Lottery game and system
AU2002367169A1 (en) Dualstage extraction blower

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2397374

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 551506

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 27877/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001902032

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001902032

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 27877/01

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2001902032

Country of ref document: EP